Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders
NCT ID: NCT00588991
Last Updated: 2025-04-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
12 participants
INTERVENTIONAL
2008-02-04
2016-11-16
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Use of Topotecan in Patients With Refractory Acute Leukemia
NCT00100477
Tipifarnib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT00101296
Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia
NCT01670084
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma
NCT01328626
A Study of Rebecsinib for Patients With Relapsed/Refractory Secondary Acute Myeloid Leukemia or High Risk Myelofibrosis
NCT07250646
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
I. To determine the feasibility, tolerability, and toxicities of ABT-888 (veliparib) when administered alone and in combination with topotecan hydrochloride with or without carboplatin in patients with relapsed or refractory acute leukemia, high-risk myelodysplasia, or aggressive myeloproliferative disorders.
II. To determine the maximum tolerated dose of ABT-888 when administered with topotecan hydrochloride and carboplatin in these patients.
III. To determine if ABT-888 when administered with topotecan hydrochloride and carboplatin can induce clinical responses in these patients.
SECONDARY OBJECTIVES:
I. To determine the pharmacokinetics of ABT-888 when administered alone and in combination with topotecan hydrochloride with or without carboplatin in these patients.
II. To obtain pharmacodynamic data regarding the ability of ABT-888 to inhibit poly (ADP-ribose) levels in leukemic blasts.
III. To obtain descriptive data regarding the mutational status and/or methylation status of key genes in selected DNA repair pathways (Fanconi complementation groups A-F, Blooms, and ataxia-telangiectasia) in leukemic blasts.
OUTLINE: This is a multicenter, dose-escalation study of veliparib.
Patients receive veliparib orally twice daily on days 1-8, 1-14, or 1-21 and topotecan hydrochloride with or without carboplatin IV continuously over 120 hours on days 3-7. Treatment repeats every 28-63 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
Patients undergo blood sample collection periodically for pharmacokinetic studies.
After completion of study therapy, patients are followed for 30 days.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment (veliparib, topotecan hydrochloride, carboplatin)
Patients receive veliparib orally twice daily on days 1-8, 1-14, or 1-21 and topotecan hydrochloride with or without carboplatin IV continuously over 120 hours on days 3-7. Treatment repeats every 28-63 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
Carboplatin
Given IV
Laboratory Biomarker Analysis
Correlative study
Topotecan Hydrochloride
Given IV
Veliparib
Given orally
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Carboplatin
Given IV
Laboratory Biomarker Analysis
Correlative study
Topotecan Hydrochloride
Given IV
Veliparib
Given orally
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Aggressive phase high-risk myeloproliferative disorders (i.e., polycythemia vera, essential thrombocythemia, or Ph-negative chronic myelogenous leukemia) meeting ≥ 1 of the following criteria:
* Marrow blasts \> 5%
* Peripheral blood blasts plus progranulocytes \> 10%
* New onset or increasing myelofibrosis OR;
* New onset or \> 25% increase in hepatomegaly or splenomegaly
* New onset constitutional symptoms (i.e., fever, weight loss, splenic pain, or bone pain)
* Patients who failed primary induction therapy or relapsed after achieving complete remission are eligible
* No active CNS leukemia; patients with a history of CNS disease must be stable for \> 3 months after treatment and off steroid treatment prior to study enrollment
* Chronic myelomonocytic leukemia meeting either of the following criteria:
* 5-19% bone marrow blasts (aggressive)
* At least 20% marrow blasts (transformation)
* ECOG performance status 0-2
* No hyperleukocytosis with \>= 50,000 blasts/uL
* AST, ALT, and alkaline phosphatase =\< 5 times upper limit of normal
* Bilirubin =\< 2.0 mg/dL
* Creatinine normal OR creatinine clearance \>= 60 mL/min
* LVEF \>= 45% by MUGA or ECHO
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception during and for 30 days after completion of study therapy
* No active disseminated intravascular coagulation
* No active uncontrolled infection
* Patients with infection that is under active treatment and controlled with antibiotics are eligible
* No other life-threatening illness
* No mental deficits and/or psychiatric history that would preclude giving informed consent or following protocol
* No prior or current seizure disorder or a history of seizure
* No more than 3 prior cytotoxic regimens
* At least 3 weeks since prior cytotoxic chemotherapy
* At least 2 weeks since prior radiotherapy
* At least 4 weeks since prior autologous or allogeneic stem cell transplantation
* No active graft-versus-host disease
* At least 1 week since prior biologic therapies, including hematopoietic growth factors
* At least 24 hours since prior hydroxyurea, steroids, imatinib mesylate, arsenic trioxide, interferon, or other noncytotoxic agents for blast count control
* No prior ABT-888
* No other concurrent chemotherapy, radiotherapy, or immunotherapy
* No concurrent antiretroviral therapy for HIV-positive patients
* No other concurrent investigational or commercial agents or therapies for this cancer
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Keith W Pratz
Role: PRINCIPAL_INVESTIGATOR
Johns Hopkins University/Sidney Kimmel Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland, United States
Mayo Clinic in Rochester
Rochester, Minnesota, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2009-00259
Identifier Type: REGISTRY
Identifier Source: secondary_id
CDR0000579626
Identifier Type: -
Identifier Source: secondary_id
J0783
Identifier Type: OTHER
Identifier Source: secondary_id
7968
Identifier Type: OTHER
Identifier Source: secondary_id
NCI-2009-00259
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.